bioAffinity Technologies, Inc. ( (BIAF) ) has released its Q3 earnings. Here is a breakdown of the information bioAffinity Technologies, Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
bioAffinity Technologies, Inc. is a biotechnology company specializing in noninvasive diagnostics for early-stage lung cancer and other lung diseases, with its flagship product being the CyPath® Lung test.
In its third quarter of 2025, bioAffinity Technologies reported a significant increase in CyPath® Lung testing revenue, despite an overall decrease in total revenue due to strategic shifts in its service offerings.
The company saw an 86% increase in CyPath® Lung revenues year-over-year, driven by higher test volumes and increased clinical adoption, particularly within the Veterans Administration. Despite a decrease in total revenue to $1.5 million, the company raised $10.4 million from equity transactions to support its operations and growth. Operating expenses were reduced by 16% due to cost-saving measures, although the net loss widened to $5.1 million, primarily due to changes in the fair value of warrants issued.
Looking ahead, bioAffinity Technologies remains focused on expanding the adoption of CyPath® Lung and enhancing its market presence, supported by new board appointments and an expanded patent portfolio. The company’s strategic actions are aimed at streamlining operations and focusing on high-margin diagnostics to drive future growth.